Research programme: pulmonary fibrosis combination therapeutic - Biotherapix/Digna Biotech

Drug Profile

Research programme: pulmonary fibrosis combination therapeutic - Biotherapix/Digna Biotech

Alternative Names: BTx201 and P17 combination therapeutic; M3 protein and P17 combination therapeutic

Latest Information Update: 30 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotherapix; Digna Biotech
  • Class
  • Mechanism of Action Chemokine receptor antagonists; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pulmonary fibrosis

Most Recent Events

  • 30 Jun 2011 Discontinued - Preclinical for Pulmonary fibrosis in Spain (unspecified route)
  • 27 Feb 2007 Preclinical trials in Pulmonary fibrosis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top